Subscribe to Updates
Get the latest creative news from FooBar about art, design and business.
- Coffee Break: Armed Madhouse – Israel’s Buffer Defense Quandary
- I Tried 12 Online Business Models. Here’s What Actually Made Money. — Gillian Perkins
- Under Right to Record Act, People Could Sue Federal Agents for First Amendment Violations
- MiB: Joe McLean, MAI Capital
- Links 6/9/2026 | naked capitalism
- Market Failure and the Market Process
- MAHA’s Meat-Loving Industrial Farming Hypocrisy
- Cautionary Tales – Undiplomatic Immunity: The Enemies Who Defeated Polio
Browsing: Therapeutics
FollowPlay Earnings CallPlay Earnings Call MiNK Therapeutics, Inc. (INKT) Q1 2026 Earnings Call May 15, 2026 8:30 AM EDT Company Participants Stefanie Perna-NacarJennifer Buell – Co-Founder,…
Operator Welcome to the Entrada Therapeutics Conference Call. [Operator Instructions] Please be advised that today’s conference is being recorded. I would now like to hand the…
Operator Good day, everyone, and welcome to the Vivos Full Year 2025 Earnings Conference Call. [Operator Instructions] This conference call is being recorded and a replay…
This article was written byFollowI hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a…
Decoy Therapeutics Inc. (DCOY) Discusses Corporate Overview and Pipeline Progress in Antiviral Drug Development Transcript
Jenene ThomasJenene Thomas Communications, LLC Okay. We are ready to get started. So good afternoon, everyone, and thank you for joining us today for our Virtual…
FollowPlay Earnings CallPlay Earnings Call ProQR Therapeutics N.V. (PRQR) Shareholder/Analyst Call April 8, 2026 10:00 AM EDT Company Participants Sarah Kiely – Vice President of Investor…
This article was written byFollowI have been investing in the stock market since I was 17 years old, and over the 25+ years since I have…
This article was written byFollowEdmund Ingham is a biotech consultant. He has been covering biotech, healthcare, and pharma for over 5 years, and has put together…
Beam Therapeutics Inc. (BEAM) Discusses Topline Phase I/II Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency Transcript
FollowPlay Earnings CallPlay Earnings Call Beam Therapeutics Inc. (BEAM) Discusses Topline Phase I/II Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency March 25, 2026 8:00 AM EDT…
Conference Call Participants Paul Matteis – Stifel Nicolaus Canada Inc., Research Division Presentation Paul MatteisStifel Nicolaus Canada Inc., Research Division Great. Thanks, everybody, for continuing on…
Useful Links
Subscribe to Updates
Get the latest creative news from FooBar about art, design and business.